Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - EyePoint Pharmaceuticals, Inc. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2011
PSIVIDA CORP.
(Exact name of Registrant as specified in its charter)
| Delaware | 000-51122 | 26-2774444 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
400 Pleasant Street
Watertown, MA 02472
(Address of Principal Executive Offices) (Zip Code)
(617) 926-5000
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On February 3, 2011, pSivida Corp. (“pSivida”) issued a press release announcing month 36, top-line results reported by pSivida’s licensee, Alimera Sciences, Inc. (“Alimera”), from its Phase 3 FAME™ Study readout of Iluvien® in patients with diabetic macular edema. Alimera has prepared webcast slides dated February 3, 2011 with respect to those results. pSivida’s press release and Alimera’s slides are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Press Release of pSivida dated February 3, 2011. | |
| 99.2 | Webcast slides of Alimera dated February 3, 2011 incorporated by reference to Exhibit 99.2 of Form 8-K of Alimera furnished to the SEC on February 3, 2011. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| pSivida Corp. | ||||
| By: | /s/ LORI FREEDMAN | |||
| Name: | Lori Freedman | |||
| Title: | Vice President Corporate Affairs, General Counsel & Secretary | |||
Dated: February 3, 2011